Quantitative MRI establishes the efficacy of PI3K inhibitor (GDC-0941) multi-treatments in PTEN-deficient mice lymphoma

Anticancer Research

Volumn 32, Issue 2, 2012, Pages 415-420

  Wullschleger, Stephan ^a   García Martínez, Juan M ^a   Duce, Suzanne L ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Drug resistance; Follicular lymphoma; GDC 0941; Mouse cancer model; MRI; PI3k inhibitor; PTEN

Indexed keywords

PICTRELISIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; CANCER GROWTH; CANCER MODEL; CANCER REGRESSION; CONTROLLED STUDY; FOLLICULAR LYMPHOMA; GENETIC ENGINEERING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMALE; HEAD AND NECK NEOPLASMS; INDAZOLES; LONGITUDINAL STUDIES; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHOSPHATIDYLINOSITOL 3-KINASES; PTEN PHOSPHOHYDROLASE; SULFONAMIDES;

EID: 84856851338     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Kummar S, Chen HX, Wright J, Holbeck S, Millin MD, Tomaszewski J, Zweibel J, Collins J and Doroshow JH: Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat Rev Drug Discov 9: 843-856, 2010.
2. Hopkins AL: Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4: 682-690, 2008.
3. Levitzki A and Klein S: Signal transduction therapy of cancer. Mol Aspects Med 31: 287-329, 2010.
4. de Bono JS and Ashworth A: Translating cancer research into targeted therapeutics. Nature 467: 543-549, 2010.
5. Prendergast G: Cancer Therapeutics: Strategies for Drug Discovery and Development. New Jersey: Wiley-Blackwell, 2004.
6. Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell 144: 646-674, 2011.
7. Gilbert CA, Daou M-C, Moser RP and Ross AH: γ-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence. Cancer Res 70: 6870-6879, 2010.
8. Cheon D-J and Orsulic S: Mouse models of cancer. Annu Rev Pathol 6: 95-119, 2011.
9. Frese KK and Tuveson DA: Maximizing mouse cancer models. Nat Rev Cancer 7: 645-658, 2007. (Pubitemid 47327410)
10. Sharpless NE and DePinho RA: Model organisms - The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 5: 741-754, 2006. (Pubitemid 44323701)
11. Becher OJ and Holland EC: Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res 66: 5526-5526, 2006.
12. Sundberg J and Tsutomu I: Genetically Engineered Mice Handbook. Florida: CRC Press, 2005.
13. Skarnes WC, Rosen B, West AP, Koutsourakis M, Bushell W, Iyer V, Mujica AO, Thomas M, Harrow J, Cox T, Jackson D, Severin J, Biggs P, Fu J, Nefedov M, de Jong PJ, Stewart AF and Bradley A: A conditional knockout resource for the genome-wide study of mouse gene function. Nature 474: 337-361, 2011.
14. Koo V, Hamilton PW and Williamson K: Non-invasive in vivo imaging in small animal research. Cell Oncol 28: 127-139, 2006. (Pubitemid 44427396)
15. Henkelman RM: Systems biology through mouse imaging centers: Experience and new directions. Annu Rev Biomed Eng 12: 143-166, 2010.
16. Marcus CD, Ladam-Marcus V, Cucu C, Bouche O, Lucas L and Hoeffel C: Imaging techniques to evaluate the response to treatment in oncology: Current standards and perspectives. Crit Rev Oncol Hematol 72: 217-238, 2009.
17. Lyons SK: Advances in imaging mouse tumour models in vivo. J Pathol 205: 194-205, 2005.
18. Podsypanina K, Ellenson LH, Nemes A, Gu JG, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE and Parsons R: Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 96: 1563-1568, 1999. (Pubitemid 29098491)
19. Huang X, Wullschleger S, Shpiro N, McGuire VA, Sakamoto K, Woods YL, McBurnie W, Fleming S and Alessi DR: Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 412: 211-221, 2008. (Pubitemid 351758227)
20. Keniry M and Parsons R: The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 27: 5477-5485, 2008.
21. Matthews DJ and Gerritsen ME: Targeting Protein Kinases for Cancer Therapy. New Jersey: Wiley-Blackwell, 2010.
22. 1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin- 1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 51: 5522-5532, 2008.
23. Salphati L, Wong H, Belvin M, Bradford D, Edgar KA, Prior WW, Sampath D and Wallin JJ: Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor gdc-0941. Drug Metab Dispos 38: 1436-1442, 2010.
24. Garcia-Martinez JM, Wullschleger S, Preston G, Guichard S, Fleming S, Alessi DR and Duce SL: Effect of PI3K-and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKBI-deficient mice. Br J Cancer 104: 1116-1125, 2011.
25. American Cancer Society: Non-Hodgkin Lymphoma. Atlanta: American Cancer Society, 2011.
26. Kilkenny C, Browne WJ, Cuthill IC, Emerson M and Altman DG: Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8: 1000412, 2010.
27. Workman P, Aboagye EO, Balkwill F, Balmain A, Brader G, Chaplin DJ, Double JA, Everitt J, Farningham DAH, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR and Eccles SA: Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102: 1555-1577, 2010.
28. Sakamoto K, McCarthy A, Smith D, Green KA, Hardie DG, Ashworth A and Alessi DR: Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J 24: 1810-1820, 2005. (Pubitemid 40769500)
29. Moore M and and IMPC Steering Committee: The International Mouse Phenotyping Consortium Initial Business Plan. Harwell, 2010.
30. He L: Quantitative Investigation of the Accuracy and Precision of Volumetric Studies Using Magnetic Resonance Imaging. MSc Thesis, University of Dundee, UK, 2011.
31. Wullschleger S, Sakamoto K, Johnstone L, Duce S, Fleming S and Alessi DR: How moderate changes in Akt T-loop phosphorylation impact on tumorigenesis and insulin resistance. Dis Model Mech 4: 95-103, 2011.